v3.25.4
SHAREHOLDERS' EQUITY - Narrative (Details)
3 Months Ended 9 Months Ended 82 Months Ended
Jul. 18, 2021
Feb. 04, 2020
USD ($)
sales_agent
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
Dec. 31, 2024
USD ($)
$ / shares
shares
Dec. 31, 2025
USD ($)
$ / shares
shares
May 21, 2024
USD ($)
May 20, 2024
USD ($)
Aug. 02, 2022
USD ($)
Aug. 01, 2022
USD ($)
Aug. 31, 2021
USD ($)
Jul. 28, 2021
USD ($)
May 26, 2021
USD ($)
Mar. 04, 2019
USD ($)
Subsidiary or Equity Method Investee [Line Items]                              
Repurchase authorized amount                       $ 20,000,000 $ 20,000,000    
Restricted Stock | 2010 Plan                              
Subsidiary or Equity Method Investee [Line Items]                              
Right to grant period 10 years                            
Equity ATM Program                              
Subsidiary or Equity Method Investee [Line Items]                              
Maximum consideration threshold   $ 100,000,000.0           $ 1,000,000,000 $ 650,000,000 $ 650,000,000.0 $ 250,000,000.0     $ 250,000,000.0 $ 50,000,000.0
Number of additional sales agents | sales_agent   2                          
Gross sales commission percentage   2.00%                       1.50%  
Number of shares sold (in shares) | shares     2,490,000 2,364,147 6,291,892 4,702,227 39,333,069                
Weighted average price per share (in usd per share) | $ / shares     $ 21.11 $ 22.68 $ 21.39 $ 23.93 $ 21.47                
Gross proceeds received     $ 52,553,000 $ 53,620,000 $ 134,582,000 $ 112,540,000 $ 844,600,000                
Net proceeds received     51,765,000 $ 52,915,000 132,661,000 $ 110,951,000 831,700,000                
Available under the equity ATM program     $ 155,400,000   $ 155,400,000   $ 155,400,000